ADC Therapeutics SA, a biotechnology company focused on clinical-stage oncology, develops antibody drug conjugates (ADCs) for patients suffering from hematologic malignancies and solid tumors. Its lead product candidates are loncastuximab tesirin (ADCT-402), an ADC that is in a phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and the trial phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as a phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal phase II clinical trial for the treatment of relapsed or refractory Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, and a phase Ib clinical trial for selected advanced solid tumors. The company is also developing clinical-stage product candidates, such as ADCT-601, which is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS and Synaffix BV ADC Therapeutics SA was incorporated in 2011 and is based in Epalinges, Switzerland. and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS and Synaffix BV ADC Therapeutics SA was incorporated in 2011 and is based in Epalinges, Switzerland. and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS and Synaffix BV ADC Therapeutics SA was incorporated in 2011 and is based in Epalinges, Switzerland.
How to buy shares of ADC Therapeutics (ADCT) – Tutorial
Do you want to buy ADC Therapeutics (ADCT) shares on the NYSE reliably and using an officially regulated broker? Are you interested in being able to invest your savings for the month and get a return on the stock market? Today I am going to show you how you can register with DEGIRO , a regulated investment broker with minimal commissions, and how you can get hold of your first shares of ADC Therapeutics SA (ADCT) (ADCT) quickly and intuitively.
The procedure is intuitive :
- First, we will create an account in Degiro, an interface in which we will invest in shares of the company ADC Therapeutics SA (ADCT), (ADCT).
- In 2nd place we will enter capital and be able to make the 1st investment in the stock market.
- When we visualize the funds, what we are going to do is locate the company ADC Therapeutics looking for its ticker, that is, ADCT.
- To finish, we only have to indicate the number of shares we want, the purchase price and the type of order.
This tutorial may have been somewhat simple for you, so I am going to summarize the procedure with images.
Tutorial, register an account in Degiro
To start we will create an account in DeGiro through this link :
It will require an e-mail, a username and a pin code to enter, and then we must continue using the link that they have sent us by mail.
DeGiro will then ask us for important information in order to validate our document . We need to have our passport number, ID or driving license, your mobile or cell phone and the account number that we will use to make our 1st deposit in IBAN format. If you don’t understand what form this format is, you can check this simple step by step we wrote .
Once our account is verified we will be able to put money from the Enter / Withdraw tab. We have the possibility of making a bank transaction that will take more or less 1 to 2 days, or proceed to make the deposit instantly thanks to Sofort, a completely secure and reliable payment gateway.
How to buy ADC Therapeutics (ADCT) shares through DeGiro
The moment we have the money we can buy our 1st share. You can select the “Place Order” button in the right corner or use the DEGIRO search engine and paste the ticker. In the following image you will see that I have written the Amazon ticker but you have to place (ADCT), the ADC Therapeutics ticker. As we are talking about an action, we will see that the related tickers are listed and there we will look to find ADC Therapeutics. What is key is that the ticker, the name of the stock and the market in which it is listed coincide. Amazon is listed on NASDAQ (NDQ) and in your case ADC Therapeutics SA (ADCT) is listed on NYSE. This step is very important so don’t get confused.
When placing the order we must be attentive to what I will explain to you . We will be able to place a limit or market order. Imagine that you want to get a share of ADC Therapeutics, but its price is currently too prominent. With this limit order we will adapt the value at which we want to make the operation and until there are no shares selling at a certain price, the acquisition of the share will not be executed. With a Degiro market order you will buy the number of shares we have suggested at the today’s selling price, which will be very close to today’s trading price.
In both cases it is essential that you look at the type of order: permanent or of the day . To give an example, in Spain, the stock market is from tomorrow until 1:00 p.m., and in the United States it corresponds to the afternoon schedule in Spain. If the order is fixed, it will last until it can be executed, but if you prefer the “of the day” option, at the end of the day, if it is not carried out, it will be deleted from your Activity file – Pending Orders.
I would love this detailed tutorial to help you invest in ADC Therapeutics. Until next time!
|Name||Title||Salary||exercised||Year of birth|
|Dr. Christopher J. Martin||Co-Founder, CEO and Director||N/A||N/A||1959|
|Mr Michael Forer LLB||Vice President, Exec. Vice President and General Counsel||N/A||N/A||1966|
|Mrs Jennifer Creel||CFO||N/A||N/A||1971|
|Mr. Robert A. Schmidt||Vice President, Corporate Controller and Accounting Director||N/A||N/A||1977|
|amanda hamilton||Investor Relations Officer||N/A||N/A||N/A|
|Mrs Susan Romanus||Chief Compliance Officer||N/A||N/A||1966|
|Dr. Peter Greaney Ph.D.||Head of Corp. Development.||N/A||N/A||1980|
|Mrs Kimberly Pope||Senior Vice President and Director of Human Resources||N/A||N/A||1967|
|Dr Patrick van Berkel||Senior Vice President of R&D||N/A||N/A||1969|
|Jay M. Feingold MD, Ph.D.||Medical Director, Head of Clinical Oncology Development. and Senior Vice President||N/A||N/A||1957|
Recent events of :
We have no recent events for this company.